---
figid: PMC3689263__ERC130099f02
figtitle: Signaling mechanisms important for endocrine resistance and which are currently
  targeted in clinical trials, combined with aromatase inhibitors
organisms:
- Homo sapiens
- Mus musculus
- Diaporthe sclerotioides
- Equus caballus
- Microbacterium aurantiacum
pmcid: PMC3689263
filename: ERC130099f02.jpg
figlink: /pmc/articles/PMC3689263/figure/fig2/
number: F2
caption: Signaling mechanisms important for endocrine resistance and which are currently
  targeted in clinical trials, combined with aromatase inhibitors. (1) IGF1 or IGF1R
  neutralizing antibodies (AMG-479 in study NCT00626106 a.o.). (2) HER-2 blocking
  therapy (trastuzumab emtansine in study NCT01745965 a.o.). (3) Inhibitors of PI3K,
  Akt, and/or mTOR pathway (everolimus in study NCT01698918 a.o.). (4) Src inhibitors
  (dasatinib in study NCT00696072 a.o.). (5) AMPK activator (metformin in study NCT01654185
  a.o.). (6) Inhibitors of Ras-Raf-MEK-MAPK pathway (MEK inhibitor AZD6244, combined
  with fulvestrant after progression on aromatase inhibitor in NCT01160718). (7) Gamma
  secretase inhibitor (RO4929097 in study NCT01208441 a.o.). (8) HDAC inhibitors (vorinostat
  in study NCT01153672 a.o.). (9) CDK4/6 inhibitor (PD0332991 in study NCT01740427
  a.o.).
papertitle: 'Aromatase inhibition 2013: clinical state of the art and questions that
  remain to be solved.'
reftext: Per Eystein LÃ¸nning, et al. Endocr Relat Cancer. 2013 Aug;20(4):R183-R201.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9669119
figid_alias: PMC3689263__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
- Equus caballus
redirect_from: /figures/PMC3689263__F2
ndex: 7e11be47-decf-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3689263__ERC130099f02.html
  '@type': Dataset
  description: Signaling mechanisms important for endocrine resistance and which are
    currently targeted in clinical trials, combined with aromatase inhibitors. (1)
    IGF1 or IGF1R neutralizing antibodies (AMG-479 in study NCT00626106 a.o.). (2)
    HER-2 blocking therapy (trastuzumab emtansine in study NCT01745965 a.o.). (3)
    Inhibitors of PI3K, Akt, and/or mTOR pathway (everolimus in study NCT01698918
    a.o.). (4) Src inhibitors (dasatinib in study NCT00696072 a.o.). (5) AMPK activator
    (metformin in study NCT01654185 a.o.). (6) Inhibitors of Ras-Raf-MEK-MAPK pathway
    (MEK inhibitor AZD6244, combined with fulvestrant after progression on aromatase
    inhibitor in NCT01160718). (7) Gamma secretase inhibitor (RO4929097 in study NCT01208441
    a.o.). (8) HDAC inhibitors (vorinostat in study NCT01153672 a.o.). (9) CDK4/6
    inhibitor (PD0332991 in study NCT01740427 a.o.).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egf
  - Erbb2
  - Igf1
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Src
  - Akt1
  - Esr1
  - Eral1
  - Zhx2
  - Mtor
  - Mdk
  - Rps6kb1
  - Cdk4
  - Gabrg2
  - EGF
  - ERBB2
  - EGFR
  - IGF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - XYLT2
  - SOS1
  - SOS2
  - SRC
  - FGR
  - FYN
  - YES1
  - AKT1
  - AKT2
  - AKT3
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - BCAR1
  - ESR1
  - ERAL1
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - RPS6KB1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - NOTCH1
  - NOTCH2
  - NOTCH3
  - NOTCH4
  - CDK4
  - WARS1
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
